
Statistical Issues in Drug Development
Stephen S. Senn(Author)
Wiley (Publisher)
2nd Edition
Published on 4. January 2008
Book
Hardback
524 pages
978-0-470-01877-4 (ISBN)
Unfortunately, price unknown
Article exhausted; check for reprint
Description
Drug development is the process of finding and producing therapeutically useful pharmaceuticals, turning them into safe and effective medicine, and producing reliable information regarding the appropriate dosage and dosing intervals. With regulatory authorities demanding increasingly higher standards in such developments, statistics has become an intrinsic and critical element in the design and conduct of drug development programmes.
Statistical Issues in Drug Development presents an essential and thought provoking guide to the statistical issues and controversies involved in drug development.
This highly readable second edition has been updated to include:
* Comprehensive coverage of the design and interpretation of clinical trials.
* Expanded sections on missing data, equivalence, meta-analysis and dose finding.
* An examination of both Bayesian and frequentist methods.
* A new chapter on pharmacogenomics and expanded coverage of pharmaco-epidemiology and pharmaco-economics.
* Coverage of the ICH guidelines, in particular ICH E9, Statistical Principles for Clinical Trials.
It is hoped that the book will stimulate dialogue between statisticians and life scientists working within the pharmaceutical industry. The accessible and wide-ranging coverage make it essential reading for both statisticians and non-statisticians working in the pharmaceutical industry, regulatory bodies and medical research institutes. There is also much to benefit undergraduate and postgraduate students whose courses include a medical statistics component.
Reviews / Votes
For all his contributions to the development and exposition of medical statistics Stephen Senn is awarded the 2009 Bradford Hill Medal by the Royal Statistical Society. ?This book is a thought provoking, intriguing, and often challenging read. The author is unafraid to tackle weighty philosophical and paradigmatic issues, and he generally does so with great skill and insight. ...this excellent book should serve to inspire both statisticians and life scientists.? (Journal of the American Statistical Association, September 2009)"For statisticians, this should be required reading for anyone considering or starting out on a career in clinical drug development. I am also quite sure that most experienced statisticians would find this a useful book to dip into on occasion ... . This book will not disappoint." (Journal of the Royal Statistical Society: Series A (Statistics in Society), April 2009)
"This book is an outstanding effort from a statistician of heroic proportions. Someone like me is only capable of sitting on the curb and applauding wildly." (Journal of Biopharmaceutical Statistics, Volume 19, Issue 1, 2009)
More details
Series
Edition
2. Auflage
Language
English
Place of publication
United States
Publishing group
John Wiley & Sons Inc
Target group
Professional and scholarly
Dimensions
Height: 24.4 cm
Width: 16.8 cm
Thickness: 3.3 cm
Weight
1042 gr
ISBN-13
978-0-470-01877-4 (9780470018774)
Schweitzer Classification
Other editions
New editions

Stephen S. Senn
Statistical Issues in Drug Development
Book
03/2021
Wiley-Blackwell
€120.50
Shipment within 15-20 days
Previous edition

Stephen Senn
Statistical Issues in Drug Development
Book
07/1997
1st Edition
Wiley
€119.00
Article exhausted; check for reprint
Person
Stephen Senn has worked for the NHS in England, as a lecturer in Scotland and in drug development in Switzerland (with CIBA-Geigy). Until recently he was Professor of Pharmaceutical and Health Statistics at University College London but since September 2003 he has been Professor of Statistics at Glasgow University. His books, Cross-over Trials in Clinical Research (1993, 2nd edition 2002) and Statistical Issues in Drug Development (1997) are published by Wiley and his latest book, Dicing with Death (2003) by Cambridge University Press. In 2001, he was the first recipient of the George C Challis award for biostatistics of the University of Florida. He is a member of the editorial boards of Statistics in Medicine, Statistical Methods in Medical Research, Pharmaceutical Statistics and Applied Clinical Trials and is a section editor for the Wiley Statistics in Practice series.
Content
Preface to the Second Edition.
Preface to the First Edition.
Acknowledgements.
1. Introduction.
Part 1: Four Views of Statistics in Drug Development: Historical, Methodological, Technical and Professional.
2. A Brief and Superficial History of Statistics for Drug Developers.
3. Design and Interpretation of Clinical Trials as Seen by a Statistician.
4. Probability, Bayes, P-values, Tests of Hypotheses and Confidence Intervals.
5. The Work of the Pharmaceutical Statistician.
Part 2: Statistical Issues: Debatable and Controversial Topics in Drug Development.
6. Allocating Treatments to Patients in Clinical Trials.
7. Baselines and Covariate Information.
8. The Measurement of Treatment Effects.
9. Demographic Subgroups: Representation and Analysis.
10. Multiplicity.
11. Intention to Treat, Missing Data and Related Matters.
12. One-sided and Two-sided Tests and Other Issues to Do with Significance and P-values.
13. Determining the Sample Size.
14. Multicentre Trials.
15. Active Control Equivalence Studies.
16. Meta-Analysis.
17. Cross-over Trials.
18. n-of-1 Trials.
19. Sequential Tr4ials.
20. Dose-finding.
21. Concerning Pharmacokinetics and Pharmacodynamics.
22. Bioequivalence Studies.
23. Safety Data, Harms, Drug Monitoring and Pharmaco-epidemiology.
24. Pharmaco-economics and Portfolio Management.
25. Concerning Pharmacogenetics, Pharmacogenomics and Related Matters.
Glossary.
Index.